AR053152A1 - Formas cristlinas y amorfas del clorhidrato 4- ciano-n-{ (2r) -2- (4- (2,3- dihidro- benzo (1,4) dioxin -5- il) - piperazin -1-il) -propil} -n- piridin -2-il-benzamida - Google Patents

Formas cristlinas y amorfas del clorhidrato 4- ciano-n-{ (2r) -2- (4- (2,3- dihidro- benzo (1,4) dioxin -5- il) - piperazin -1-il) -propil} -n- piridin -2-il-benzamida

Info

Publication number
AR053152A1
AR053152A1 ARP060100776A ARP060100776A AR053152A1 AR 053152 A1 AR053152 A1 AR 053152A1 AR P060100776 A ARP060100776 A AR P060100776A AR P060100776 A ARP060100776 A AR P060100776A AR 053152 A1 AR053152 A1 AR 053152A1
Authority
AR
Argentina
Prior art keywords
dioxin
piperazin
benzo
crystlin
benzamida
Prior art date
Application number
ARP060100776A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053152A1 publication Critical patent/AR053152A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a formas cristalinas y amorfas del clorhidrato 4-ciano-N-{(2R)-2-[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-N-piridin-2-il-benzamida, así como también a las composiciones de los mismos y los métodos para usar dichas composiciones, utiles como antagonista del receptor de 5HT1A.
ARP060100776A 2005-03-01 2006-03-01 Formas cristlinas y amorfas del clorhidrato 4- ciano-n-{ (2r) -2- (4- (2,3- dihidro- benzo (1,4) dioxin -5- il) - piperazin -1-il) -propil} -n- piridin -2-il-benzamida AR053152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65757505P 2005-03-01 2005-03-01

Publications (1)

Publication Number Publication Date
AR053152A1 true AR053152A1 (es) 2007-04-25

Family

ID=36659970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100776A AR053152A1 (es) 2005-03-01 2006-03-01 Formas cristlinas y amorfas del clorhidrato 4- ciano-n-{ (2r) -2- (4- (2,3- dihidro- benzo (1,4) dioxin -5- il) - piperazin -1-il) -propil} -n- piridin -2-il-benzamida

Country Status (19)

Country Link
US (2) US20070027162A1 (es)
EP (1) EP1853593A1 (es)
JP (1) JP2008531694A (es)
KR (1) KR20070112797A (es)
CN (1) CN101137648A (es)
AR (1) AR053152A1 (es)
AU (1) AU2006218845A1 (es)
BR (1) BRPI0609370A2 (es)
CA (1) CA2599588A1 (es)
CR (1) CR9319A (es)
GT (1) GT200600098A (es)
IL (1) IL185267A0 (es)
MX (1) MX2007010524A (es)
NI (1) NI200700217A (es)
NO (1) NO20074254L (es)
PE (1) PE20061344A1 (es)
RU (1) RU2007131044A (es)
TW (1) TW200700413A (es)
WO (1) WO2006093853A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600403A (es) * 2005-09-09 2007-09-19 Composiciones y formas de dosificacion farmaceuticas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645681B2 (en) * 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5568992A (en) * 1995-05-19 1996-10-29 Caterpillar Paving Products Inc. Screed control system for an asphalt paver and method of use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6287839B1 (en) * 1997-11-19 2001-09-11 Genencor International, Inc. Cellulase producing actinomycetes, cellulase produced therefrom and method of producing same
US6127062A (en) * 1998-03-24 2000-10-03 Duracell Inc End cap seal assembly for an electrochemical cell
TR200100698T2 (tr) * 1998-09-10 2001-07-23 F.Hoffmann-La Roche Ag 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri
IT1318394B1 (it) * 2000-03-17 2003-08-25 Enichem Spa Processo per la preparazione di 1-esene.
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
RU2315762C2 (ru) * 2002-03-12 2008-01-27 Уайт Способ синтеза хиральных n-арилпиперазинов
US7091349B2 (en) * 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
ES2283762T3 (es) * 2002-03-12 2007-11-01 Wyeth Preparacion de acido n1-(2'-piridil)-1,2-propanodiaminosulfamico y su uso en la sintesis de piperazinas biologicamente activas.
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
TWI257220B (en) * 2005-03-25 2006-06-21 Ind Tech Res Inst Cross-layer rate adaptation mechanism for WLAN

Also Published As

Publication number Publication date
CR9319A (es) 2008-01-21
US20090192311A1 (en) 2009-07-30
RU2007131044A (ru) 2009-04-10
CN101137648A (zh) 2008-03-05
US20070027162A1 (en) 2007-02-01
KR20070112797A (ko) 2007-11-27
EP1853593A1 (en) 2007-11-14
CA2599588A1 (en) 2006-09-08
JP2008531694A (ja) 2008-08-14
WO2006093853A1 (en) 2006-09-08
MX2007010524A (es) 2008-01-16
TW200700413A (en) 2007-01-01
GT200600098A (es) 2006-11-09
IL185267A0 (en) 2008-02-09
AU2006218845A1 (en) 2006-09-08
PE20061344A1 (es) 2007-01-03
NO20074254L (no) 2007-09-24
BRPI0609370A2 (pt) 2010-03-30
NI200700217A (es) 2008-07-24

Similar Documents

Publication Publication Date Title
EA201200506A1 (ru) СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ)БЕНЗОЛА
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
ECSP109987A (es) Métodos y compuestos útiles para preparar inhibidores del co-transportador 2 sodio glucosa
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BRPI0608221A2 (pt) métodos para preparação de um composto, e para preparar seletivamente um composto de nitrila, e, composto
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
HN2010001563A (es) Compuestos
ATE483707T1 (de) 2-cyclopropylthiazolderivate
GT200600158A (es) Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina
PE20070179A1 (es) Derivados de purina como agonistas del receptor de adenosina a2
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
CR10963A (es) Compuestos de 2-amino pirimidina
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
PE20160846A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c
SV2010003725A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
DE602006020450D1 (de) Ykinin-rezeptorantagonisten
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
EA201101150A1 (ru) Ключевые промежуточные соединения для синтеза розувастатина или его фармацевтически приемлемых солей
AR053152A1 (es) Formas cristlinas y amorfas del clorhidrato 4- ciano-n-{ (2r) -2- (4- (2,3- dihidro- benzo (1,4) dioxin -5- il) - piperazin -1-il) -propil} -n- piridin -2-il-benzamida
DOP2006000124A (es) Potenciadores del receptor ampa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal